F508del CFTR gene mutation in patients with allergic bronchopulmonary aspergillosis

References

• Zielenski J, Tsui LC. Cystic fibrosis: Genotypic and phenotypic variations. Ann Rev Genetics 1995;29:777–807.
   PubMed Web of Science ®Google Scholar
• Buchanan PJ, Ernst RK, Elborn JS, Schock B. Role of CFTR, Pseudomonas aeruginosa and Toll-like receptors in cystic fibrosis lung inflammation. Biochem Soc Trans 2009;37:863–867.
   PubMed Web of Science ®Google Scholar
• Harris A. Cystic fibrosis gene. Br Med Bull 1992;48:738–753.
   PubMed Web of Science ®Google Scholar
• The Leeds Method of Management. 2008. The genetics of Cystic Fibrosis [online]. Leeds Regional Adult and Paediatric Cystic Fibrosis Units, St James's University Hospital, Leeds, UK. Available from: http://www.cysticfibrosismedicine.com
   Google Scholar
• Maurya N, Awasthi S, Dixit P. Association of CFTR gene mutation with bronchial asthma. Indian J Med 2012;135:469–478.
   Google Scholar
• Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, et al. Allergic bronchopulmonary aspergillosis: Review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013;43:850–873.
   PubMed Web of Science ®Google Scholar
• Eaton TE, Weiner Miller P, Garrett JE, Cutting GR. Cystic fibrosis transmembrane conductance regulator gene mutations: Do they play a role in the aetiology of allergic bronchopulmonary aspergillosis? Clin Exp Allergy 2002;32:756–761.
   PubMed Web of Science ®Google Scholar
• Miller PW, Hamosh A, Macek M Jr, Greenberger PA, MacLean J, Walden SM, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet 1996;59:45–51.
   PubMed Web of Science ®Google Scholar
• Armstead J, Morris J, Denning DW. Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis. PLoS One 2014;9:e98502.
   PubMed Web of Science ®Google Scholar
• Chaudhary N, Datta K, Askin FB, Staab JF, Marr KA. Cystic fibrosis transmembrane conductance regulator regulates epithelial cell response to Aspergillus and resultant pulmonary inflammation. Am J Respir Crit Care Med 2012;185:301–310.
   PubMed Web of Science ®Google Scholar
• Chaudhary N, Marr KA. Impact of Aspergillus fumigatus in allergic airway diseases. Clin Transl Allergy 2011;1:4.
   PubMedGoogle Scholar
• Marchand E, Verellen-Dumoulin C, Mairesse M, Delaunois L, Brancaleone P, Rahier JF, et al. Frequency of cystic fibrosis transmembrane conductance regulator gene mutations and 5T allele in patients with allergic bronchopulmonary aspergillosis. Chest 2001;119:762–767.
   PubMed Web of Science ®Google Scholar
• Anonymous. Devyser CFTR core. Available from: http://devyser.com/apps/devyser-cftr-core [last assessed 02 April, 2017.]
   Google Scholar
• Lebecque P, Pepermans X, Marchand E, Leonard A, Leal T. ABPA in adulthood: A CFTR-related disorder. Thorax 2011;66:540–541.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Khan A, Aggarwal AN, Gupta D. Link between CFTR mutations and ABPA: A systematic review and meta-analysis. Mycoses 2012;55:357–365.
   PubMed Web of Science ®Google Scholar
• Lambourne J, Agranoff D, Herbrecht R, Troke PF, Buchbinder A, Willis F, et al. Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2009;49:1486–1491.
   PubMed Web of Science ®Google Scholar
• Harrison E, Singh A, Morris J, Smith NL, Fraczek MG, Moore CB, et al. Mannose-binding lectin genotype and serum levels in patients with chronic and allergic pulmonary aspergillosis. Int J Immunogenet 2012;39:224–232.
   PubMed Web of Science ®Google Scholar
• Vaid M, Kaur S, Sambatakou H, Madan T, Denning DW, Sarma PU. Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. Clin Chem Lab Med 2007;45:183–186.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Bansal S, Chakrabarti A. Are allergic fungal rhinosinusitis and allergic bronchopulmonary aspergillosis lifelong conditions? Med Mycol 2017;55:87–95.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Therneau TM, Kyle RA. Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc. 2001;76:476–87.
   PubMed Web of Science ®Google Scholar
• Jones MM, Seilheimer DK, Pollack MS, Curry M, Crane MM, Rossen RD. Relationship of hypergammaglobulinemia, circulating immune complexes, and histocompatibility antigen profiles in patients with cystic fibrosis. Am Rev Respir Dis 1989;140:1636–1639.
   PubMed Web of Science ®Google Scholar
• Girodon E, Cazeneuve C, Lebargy F, Chinet T, Costes B, Ghanem N, et al. CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet 1997;5:149–155.
   PubMed Web of Science ®Google Scholar
• Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial. Lancet Respir Med 2014;2:527–538.
   PubMed Web of Science ®Google Scholar
• Milla CE, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M. Lumacaftor/ivacaftor in patients aged 6–11 sources with cystic fibrosis and homozygous for F508del-CFTR. Am J Respir Crit Care Med 2017;195:912–920.
   PubMed Web of Science ®Google Scholar
• Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015;373:220–231.
   PubMed Web of Science ®Google Scholar
• Sermet-Gaudelus I. Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation. Eur Respir Rev 2013;22:66–71.
   PubMedGoogle Scholar